Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|January 24, 2025

Key Strategies for Preventing CRS and ICANS

Author(s)Ryan Haumschild, PharmD, MS, MBA, CPEL, John Allan, MD, Tara Graff, MD

Panelists discuss key strategies for preventing cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) in patients receiving bispecific therapies for B-cell lymphomas.

Episodes in this series

EP. 1 ASH 2024 Updates on Bispecific Therapies in B-Cell Lymphomas

EP. 1 ASH 2024 Updates on Bispecific Therapies in B-Cell Lymphomas

EP. 2 Emerging Data for Odronextamab in DLBCL

EP. 2 Emerging Data for Odronextamab in DLBCL

EP. 3 Sequencing Consequences for Earlier Line Use of Bispecifics in B-Cell Lymphomas

EP. 3 Sequencing Consequences for Earlier Line Use of Bispecifics in B-Cell Lymphomas

EP. 4 Exploring Bispecifics in Earlier Lines of Therapy for B-Cell Lymphomas

EP. 4 Exploring Bispecifics in Earlier Lines of Therapy for B-Cell Lymphomas

EP. 5 ASH 2024 Highlights: Bispecifics in Combination Therapies for B-Cell Lymphomas

EP. 5 ASH 2024 Highlights: Bispecifics in Combination Therapies for B-Cell Lymphomas

EP. 6 MAIC Analyses and Bispecific Therapies: Guiding Treatment Decisions in B-Cell Lymphomas

EP. 6 MAIC Analyses and Bispecific Therapies: Guiding Treatment Decisions in B-Cell Lymphomas

EP. 7 Understanding CRS and ICANS: Real-World Incidence and Key Patient Risk Factors

EP. 7 Understanding CRS and ICANS: Real-World Incidence and Key Patient Risk Factors

EP. 8 Key Strategies for Preventing CRS and ICANS

EP. 8 Key Strategies for Preventing CRS and ICANS

EP. 9 Step-Up Dosing Protocols and Infection Prevention Strategies for Bispecifics in B-Cell Lymphomas

EP. 9 Step-Up Dosing Protocols and Infection Prevention Strategies for Bispecifics in B-Cell Lymphomas

EP. 10 Overcoming Logistical Hurdles in Bispecific Therapy Implementation

EP. 10 Overcoming Logistical Hurdles in Bispecific Therapy Implementation

EP. 11 Successful Implementation of Bispecific Therapies: Expert Recommendations

EP. 11 Successful Implementation of Bispecific Therapies: Expert Recommendations

EP. 12 Benefits of Implementing Bispecific Therapies in the Community

EP. 12 Benefits of Implementing Bispecific Therapies in the Community

EP. 13 Bridging the Gap: Enhancing Communication on Bispecifics Between Academic and Community Centers

EP. 13 Bridging the Gap: Enhancing Communication on Bispecifics Between Academic and Community Centers

EP. 14 Final Thoughts on Bispecifics in B-Cell Lymphomas From ASH 2024

EP. 14 Final Thoughts on Bispecifics in B-Cell Lymphomas From ASH 2024

Video content above is prompted by the following:

What are your key strategies for preventing CRS and ICANS in patients receiving bispecific therapies for B-cell lymphomas?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Road Ahead: Personalized Therapy, Combination Approaches, and Key Takeaways in Extrapulmonary Neuroendocrine Carcinoma

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

July 20th 2026

SYNCHRONIZE-1 Through a Hepatologist's Lens: Liver Fat Reduction, Visceral Fat, and What Comes Next

ByNadege Gunn, MD

July 17th 2026

Navigating Treatment Sequencing and Defining Failure in Moderate-to-Severe Atopic Dermatitis

ByAngela J. Lamb, MD

July 17th 2026

Beyond GLP-1: The Biological Case for Dual Incretin Therapy in MASH

ByNadege Gunn, MD

July 17th 2026

Emerging Data and the Future Treatment Landscape in Extrapulmonary Neuroendocrine Carcinoma: Novel Therapies, Algorithms, and Combination Strategies

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

July 13th 2026

Trending on AJMC

Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029

Fifth Death Confirmed in NYC Legionnaires' Outbreak

Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial

Contextualizing Golcadomide's Efficacy Signal in the RRFL Landscape

The Role of Radiotherapy in Advanced Follicular Lymphoma